pH Pharma is a new drug development company that is developing treatments for glaucoma and NASH

PINOTBIO is a company specializing in new drug development and is currently researching and developing targeted drug therapy for cancer and glaucoma treatments

Plasmapp is a medical solution company that works on developments in prevention, rehabilitation, and treatment in the medical field based on plasma technology

FatiAbGen is a company that specializes in new drug development, currently developing anticancer drugs and allergy treatments based on the RIT (Recombinant immunotoxin) platform

Panolos Bioscience specializes in protein structure and develops anticancer drugs using αART, an independent drug development platform

Ticaros Co., Ltd. is a biotech company specializing in next-generation cell gene therapy with its main focus on developing CAR-T immunotherapy

TMD LAB is a medical device company that researches and develops implant medical devices using shape memory polymer-based technology

CLECELL Co., Ltd, is a life science venture company developing precision medicine diagnostic methods and artificial skin models through its independently-developed bioprinting platform

Cureverse is a company that specializes in developing low-molecular compound-based treatments for intractable CNS diseases. Its main pipeline in development is a brain disease treatment targeting transcriptional regulators

CuriBio is an American company with a platform for inducing the maturation of cells derived from induced pluripotent stem cells and provides services to verify the safety and efficacy of new drugs and to screen new drug candidates through the formation of a three-dimensional structure of human iPSC-derived cardiomyocytes and muscle cells

Quratis is a bio-venture that is currently developing a tuberculosis vaccine for adolescents and adults, as well as an immune booster platform technology and COVID vaccines

GeneCker, a company developing a genome-testing platform using CRISPR genetic scissors, develops liquid biopsy-based companion diagnostics

GenoBio currently provides medical devices and services with a foundation in technology that accurately and quickly separates and detects circulating tumor cells (CTCs) from a small amount of whole blood

JD Bioscience is a new drug development company developing metabolic disease treatments and is working on treatments for non-alcoholic steatohepatitis, etc.

Zymedi is a new drug development company based on protein synthetase and is developing treatments for intractable diseases such as pulmonary arterial hypertension

INTIN is a digital healthcare company that develops and offers solutions such as digital-based ovulation analyzers and sperm analyzers

inCerebro is a company with technology enabling rapid and effective drug development by combining molecular modeling applied with quantum mechanics and artificial intelligence (AI) and is developing innovative new drugs such as anticancer drugs

EOFLOW develops and manufactures wearable medical injectors and related systems and software products

IMMUNO MAX Co., Ltd. is a biotechnology company specializing in biopharmaceuticals based on immunology and is developing allogeneic gamma delta CAR-T cell therapies and animal cell lines that produce high-efficiency biopharmaceuticals

Ubix Therapeutics develops the pipeline for blood cancer treatment and immunotherapy based on the independently-developed platform by using target protein degradation (TPD)

As a new biomaterials R&D subsidiary of OliPass Co., Ltd., OliPass RNA Co., Ltd. researches, develops, manufactures, and sells basic cosmetics and hair care products by applying its parent company's biotechnology to cosmetics

AUTOTELIC Bio is a new drug R&D company based on antisense oligonucleotide (ASO) technology and is developing immune-targeting dual-function anticancer drugs

MDsquare is a company specializing in telemedicine and smart healthcare that has launched a contact-free treatment app and is currently developing a premium healthcare platform service customized for each individual

Nventric is a medical device company developing next-generation stent retrievers to treat acute ischemic strokes

Exorenal is a U.S.-based medical device company that develops artificial kidneys and kidney dialysis devices and mainly focuses on the POCT hemodialysis business

APITBIO is a bio venture company that develops antibody-based anticancer drugs and currently possesses antibody and dual antibody platforms

Rznomics, a company specializing in gene therapy products, currently develops anticancer drugs and rare disease treatments based on RNA substitution enzymes

Avelos Therapeutics is a synthetic lethality-specialized anti-cancer drug development company currently developing anti-cancer drugs targeting substances involved in DNA damage response, cell cycles, and more

CTCELLS is a cancer diagnosis and drug development company based on liquid biopsy testing and NK engineering technology

SOLBIO is a company specializing in the early diagnosis of cancer with a patent in the early diagnosis platform technology for blood exosome-based multiple cancer/cardiovascular/nervous system diseases

SOL is a bio company that develops innovative bio and medical device products based on lens-free optical sensors that use only semiconductors

SELECXINE is a biopharmaceutical development company based on its independent antibody development platform. Currently, it is developing an anticancer immunotherapeutic treatment that selectively stimulates immune cells only that are effective against tumor cells

CEFO Bio is a new drug development company mainly focusing on stem cell therapy for bone defects

BnH Research is a company that specializes in the development of new drugs, currently developing treatments for degenerative brain diseases based on the mechanism of improving cognitive function by reactivating the neuroplasticity of the adult cerebral cortex

VasThera is a new drug development company that aims to develop treatments for cardiovascular and cancer diseases by targeting new redox signal communication

Established in 2018, Monitor Corporation is a company that has been developing medical imaging diagnosis and analysis solutions using artificial intelligence (AI) technology. Its representative product, "LuCAS," uses AI technology to automatically analyze and diagnose chest CT images, improving work efficiency in the medical field

Novmetapharma is a company that is currently developing innovative new drugs based on differentiated mechanisms (activation of AMPK Sirt 1 and Nrf2 pathways) using new substances for metabolic diseases and aims to enter the global metabolic disease treatment market through original technologies and efficient development systems

Novorex is a new drug development company that aims to develop a treatment for cancer and CNS diseases through the prediction and verification of small molecules that act on disease-targeting proteins such as GPCR with the exquisite latest technologies, including artificial intelligence (AI)

PDC line pharma is currently developing the world’s first and only anti-cancer vaccine based on off-the-shelf dendritic cell, and it has proven to be efficient in T-cell vitalization and immune reaction induction compared to existing dendritic cell vaccines. It is currently conducting clinical trials on non-small cell lung cancer patients.

Hypertension treatment medical appliances.
Kalos medical is developing treatment devices for resistant hypertension patients (patients with blood pressure not showing signs of improvement with the corresponding medication). This treatment device delivers high-frequency energy to renal artery to suppress sympathetic nerves spread throughout exterior walls of blood vessels to improve blood pressure and it is currently undergoing clinical studies.

Operation of medical appliance business as a platform for development of open innovation medical device development
Solmedix has constructed the MOSAIC platform, a cooperative business model to efficiently commercialize ideas in medical fields, and it has improved the possibilities of success for medical appliance businesses by determining the commercialization opportunities in clinical trials, markets, technologies, permits, and insurance ahead of time.

Rare disease patient data management software
Humanscape is a company creating value and contributing to development and research of medication through data generated by patients with rare disease. This company builds and operates a rare disease patient network based on block chain technology, and delivers this data to pharmaceutical companies or research institutes to assist them in research of rare diseases and development of pharmaceuticals.

Healthcare IT platform.
Immunemed has independently developed a new antibody treatment using the innate immune system and is expanding its application to hepatitis B, influenza, COVID-19, etc. For hepatitis B, it is in clinical trial phase 2 in Korea, and global clinical trial phase 2 for COVID-19 medication. Also, it is producing and selling kits to diagnose disease using the quick diagnosis method of lateral flow assay for infectious diseases such as Hantaan virus, leptospirosis, tsutsugamushi disease, dengue fever, dengue hemorrhagic fever, and typhoid.

Healthcare IT platform.
Lifesemantics is a company providing general health management service based on LifeRecord platform. It has been delivering health care services through numerous insurance companies and construction companies. Also, it is developing digital medications for many diseases.

Based on over 20 years of experience in stem cells and exosome research, Brexogen is in possession of independently developed exosome platform (BG-Platform) which has overcome the limitations of exosome medications in quality management, mass production, etc. The major pipelines consist of atopic dermatitis medication, non-alcohol steatohepatitis medication, etc.

Onegene biotechnology is developing multi-target medications for treatment of complex and chronic diseases through the protein combination platform ‘UniStac’ technology based on independently developed albumin. Major pipelines consist of development of non-alcoholic steatohepatitis (NASH) medication, cancer immunotherapy, etc.

PharosiBio is developing drugs for rare incurable diseases through open innovation strategy through the new drug development platform ‘Chemiverse’ based on its independently developed big data and AI technology. Its major pipelines consist of PHI-101 which is in global clinical trial phase 1 for acute myelogenous leukemia and clinical trial phase 1 for ovarian cancer in Korea.

Nexel is leading the iPSC-induced differentiation technology based on over 20 years of stem cell research experience. It has been promoting globalization of the first new drug toxicity evaluation platform in Korea using functional somatic cells originating from stem cells, and it is developing protein medications developed from intercellular secretion originating from human stem cells for liver fibrosis, alcoholic hepatitis, and myocardial infarction indications.

Cha Vaccine Institute has constructed the next-generation immune booster platform to develop next-generation vaccines and immunotherapy medications. The pipelines consist of clinical trial phase 2b approval for hepatitis B treatment vaccine in Korea, and clinical trial phase 1 approval for hepatitis B prevention vaccine in Korea.

Olipass is developing new RNA medication based on its OliPass PNA (peptide nucleic acid) platform for development of next-gen RNA medication. Its major pipelines consist of clinical trial phase 2a approval for non-opioid arthritis pain medication in Australia, and clinical trial phase 1 approval in the UK.

Bridgebiotherapeutics is currently in global clinical trial phase 2 for inflammatory disease medication, clinical trial phase 1/2 for molecular targeted cancer therapy medication in Korea, and clinical trial phase 1 for respiratory disease medication in the US based on its global clinical development expertise and innovative new drug R&D expertise.

Ngenebio combines the ICT & big data technology of KT and precision diagnosis platform technology to develop the first precision diagnosis technology in Korea to provide optimal customized treatment methods for patients by accurately extracting genes related to certain diseases and interpreting them through genome analysis technology based on the ‘mass genome platform technology’. For precision diagnosis examination panel based on next-generation sequencing (NGS), there is the BRCAaccuTest product which has obtained item authorization (Class II) from the Ministry of Food and Drug Safety in Korea and the first certification for in vitro diagnostic medical appliance from Europe in Asia, and the company is currently developing HLA precision diagnosis products, companion diagnostic technology, etc.

Oncorus is a company stationed in the US developing oncolytic virus anti-cancer medication based on the next-gen anti-cancer virus platform. It has two base pipelines consisting of HSV (herpes simplex virus) and synthetic virus platform. Its major pipelines consist of independent US FDA Phase 1 and joint US FDRA Phase 1 with Keytruda.

Curacle is developing various incurable vascular endothelial dysfunction disease related medications based on the SOLVADYS® (Solve of Vascular Dysfunction) platform specialized for development of endothelial dysfunction blockers (EDB). Its major pipelines consist of clinical trial phase 3 approval for IND for oral diabetic nephropathy medication in Korea, clinical trial phase 2 approval for new oral macular degeneration medication in Korea, and US FDA clinical trial phase 1 approval for oral diabetic maculopathy medication, etc.

Development of Alzheimer’s disease diagnosis kits
Peoplebio is developing and manufacturing products to diagnose altered protein diseases (primarily degenerative brain diseases) through blood tests. Its flagship product is the Alzheimer’s disease diagnosis kit and it is a product that can effectively detect beta amyloid in the blood, and it is being sold with authorization from the Ministry of Food and Drug Safety.

Development of molecular diagnosis device and platforms.
Optolane possesses semiconductor and bio convergence technology and it currently develops and sells molecular diagnosis devices and cartridges. It has a product lineup that is less sensitive compared to the digital PCR/real-time PCR in the market based on semiconductor technology, and it is developing and selling products that can target viral and cancer related diseases for diagnosis.